TCT-792 Treatment and Clinical Outcomes of Transcatheter Heart Valve Thrombosis: Multi-center Registry
نویسندگان
چکیده
منابع مشابه
Treatment and clinical outcomes of transcatheter heart valve thrombosis.
BACKGROUND Valve thrombosis has yet to be fully evaluated after transcatheter aortic valve implantation. This study aimed to report the prevalence, timing, and treatment of transcatheter heart valve (THV) thrombosis. METHODS AND RESULTS THV thrombosis was defined as follows (1) THV dysfunction secondary to thrombosis diagnosed based on response to anticoagulation therapy, imaging modality or ...
متن کاملVery late transcatheter heart valve thrombosis
We describe a case of very late transcatheter heart valve (THV) thrombosis of a first-generation SAPIEN prosthesis (Edwards Lifesciences, Irvine, CA) implanted in a 64-year-old woman with severe symptomatic aortic stenosis. More than 54 mo after implantation, she presented with severe symptomatic prosthesis dysfunction (stenosis) which was successfully treated with oral anticoagulation. To our ...
متن کاملTCT-670 Optimal Transcatheter Heart Valve Sizing in Aortic Valve in Valve Implantation: Insights from the Valve in Valve International Data (VIVID) Registry.
aortic valve area (1.33 0.41 cm2 vs. 1.52 0.5 cm2). In a multivariate analysis for elevated mean gradients within those with small surgical valves, CoreValve use (OR 0.56, CI 0.31 – 0.97, p 1⁄4 0.04), true internal diameter (OR 0.72, CI 0.59 – 0.87, p 1⁄4 0.001), THV size (OR 0.79, CI 0.65 – 0.97, p 1⁄4 0.02) and baseline regurgitation (OR 0.45, CI 0.21 – 0.93, p 1⁄4 0.03) were identified as pr...
متن کاملEarly- and mid-term outcomes after transcatheter aortic valve implantation. Data from a single-center registry
INTRODUCTION Transcatheter aortic valve implantation (TAVI) is a less invasive treatment option for elderly, high-risk patients with symptomatic severe aortic stenosis (AS) than aortic valve replacement. More importantly, TAVI improves survival and quality of life as compared to medical treatment in inoperable patients. AIM To assess early- and mid-term clinical outcomes after TAVI. MATERIA...
متن کاملOutcomes After Transcatheter Aortic Valve Replacement Using a Novel Balloon-Expandable Transcatheter Heart Valve: A Single-Center Experience.
OBJECTIVES Evaluation of 30-day outcomes after transcatheter aortic valve replacement (TAVR) with the novel balloon-expandable SAPIEN 3 (S3) transcatheter heart valve (THV) (Edwards Lifesciences, Irvine, California) emphasizing the updated Valve Academic Research Consortium (VARC-2) criteria. BACKGROUND Preliminary data on clinical performance with the S3 THV are promising. However, informati...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the American College of Cardiology
سال: 2013
ISSN: 0735-1097
DOI: 10.1016/j.jacc.2013.08.1544